MT Newswires
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
Alnylam Pharmaceuticals Inc. News
Latest updates and market news for ALNY
14 news
Jan 12 - Jan 18, 2026
Page 1
MT Newswires
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,927, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
MT Newswires
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,008,766, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
MT Newswires
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,475,157, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
MT Newswires
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,929, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
Simply Wall St.
Is It Time To Reassess Alnylam (ALNY) After Recent Share Price Pullback?
📊
AI Sentiment
Positive
7/10
Clinical Trials Arena
JPM26: 2025 a “breakout year” for rare disease biotechs
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
📊
AI Sentiment
Positive
7/10
Bloomberg
Alnylam Pharmaceuticals CEO on Development Goals, Profitability
📈
AI Sentiment
Highly Positive
8/10
Investor's Business Daily
JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won
➖
AI Sentiment
Neutral
4/10
MarketBeat
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf.
📈
AI Sentiment
Highly Positive
10/10
Share this news page